collaboration-proxygen-molecular-glue-degraders
Boehringer Ingelheim collaborates with Proxygen to explore molecular glue degraders – a novel approach to fight cancer.
Search
Research Collaborations
Research Collaborations
Breaking prejudice in lung cancer
At Boehringer Ingelheim, addressing patient needs and fighting stigma in lung cancer care are two focus topics of the patient engagement team in oncology.
Targeting HER2 in cancer: The story of zongertinib
We discovered zongertinib, an HER2 tyrosine kinase inhibitor, being developed as a potential oral treatment for people with HER2-mutated NSCLC
Winners of the 2020 European PRRS Research Award
Winners of the 2020 European PRRS Research Award announced Three winner awarded 25,000 euro each for their research.
Research Beyond Borders Partnering
Our Research Beyond Borders team is looking for emerging science and technology opportunities. Learn more about partnering with us.
2021 PRRS Research Award winners announced
The 2021 European PRRS Research Award winners announced
Gastrointestinal Cancers
Gastrointestinal Cancers
Winners of the 2019 European PRRS Research Award
Winners of the 2019 European PRRS Research Award announced.
Research ruminant animal health well-being
Boehringer Ingelheim supports young scientists and veterinarians dedicated to ruminant health research
Lung Cancer
Lung Cancer
Immunology Respiratory Research
Find out more about our research and development in Immunology & Respiratory diseases
Facing lung cancer
Keith and Heather talk about their experiences of facing lung cancer as a family and finding purpose after treatment.
Research Beyond Borders overview
Learn more about how our Research Beyond Borders team is uncovering new ideas and new science.
Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80-85% of all lung cancer cases. Find out more about testing and treatment here.
Dietary Advice for Specific Cancers
Learn more about dietary advice for specific cancers from Taking Cancer On Through Flavour
Cancer's Big 4
We have a robust pipeline of clinical assets including cancer cell-directed therapies, for which we are investigating the key drivers of cancer such as P53 and KRAS.
KISIMA® cancer vaccine
KISIMA® Cancer Vaccine
Partnership with Precision Health Research, Singapore
Boehringer Ingelheim joins forces with Precision Health Research, Singapore with the aim of transforming healthcare and improving patient outcomes in Singapore and beyond.
High Protein Diets for Cancer Patients
Learn more about the benefits of high protein diets for cancer patients from Taking Cancer On Through Flavour
Transforming Cancer Care
Transforming cancer care requires a diversity of minds.
Trailr2-cdh17-antibody-phase1-trial
Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
Weight Loss from Cancer Treatment
Discover advice on how to put weight back on following cancer treatment from Taking Cancer On Through Flavour
The Research Process
The Research Process
Taking cancer on together
Through their work, our colleagues from around the world hope to empower patients to Take Cancer On.